Abstract: Certain aspects of the present disclosure provide techniques for semantically contextualizing structured and unstructured data, extracting and making sense of domain knowledge, and performing semantic-driven optimization to provide generic, scalable, autonomous and real-time performance management within a built environment domain.

Abstract: Certain aspects of the present disclosure provide techniques for semantically contextualizing structured and unstructured data, extracting and making sense of domain knowledge, and performing semantic-driven optimization to provide generic, scalable, autonomous and real-time performance management within a built environment domain.

Abstract: Systems and methods are provided that may reduce the battery consumption footprint of a user equipment (UE) in a communications network, such as an LTE network, as well as reduce over the air signaling over the LTE network, and reduce call set-up latency for circuit switched fallback (CSFB) calls. When Idle Mode Signaling Reduction (ISR) is active in the communications network, and when the coverage area of the communications network, such as the LTE network, overlaps with the coverage area of one or more legacy radio access technology (RAT) networks, such as 2G and 3G networks, a module within the UE allows the UE to directly establish a CSFB call over one of the legacy RAT networks instead of initially servicing the CSFB call over the LTE network.

Abstract: A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound selected from the group comprising an alkali metal alkyl sulfate and a polyoxyethylene sorbitan monooleate, (c) a block copolymer of polyoxyethylene and polyoxypropylene, (d) at least one additional micelle-forming compound, and (e) a suitable solvent. The invention also provides a metered dose dispenser (aerosol or non-aerosol) containing the present formulation and a method of administering insulin using the metered dose dispenser comprising administering split doses of a formulation containing insulin before and after each meal.

Abstract: A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound selected from the group comprising an alkali metal alkyl sulfate and a polyoxyethylene sorbitan monooleate, (c) a block copolymer of polyoxyethylene and polyoxypropylene, (d) at least one additional micelle-forming compound, and (e) a suitable solvent. The invention also provides a metered dose dispenser (aerosol or non-aerosol) containing the present formulation and a method of administering insulin using the metered dose dispenser comprising administering split doses of a formulation containing insulin before and after each meal.

Abstract: Composition, non-aerosol dispenser containing the composition, and method of raising the blood glucose level of an individual comprising administering an effective amount of the composition to an oral mucosa of the individual. The composition comprises: a. an effective amount of glucose, b. an effective amount of at least one absorption enhancer chosen from lecithin, hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening primrose oil, menthol, trihydroxy oxo cholanyl glycine, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers, polidocanol alkyl ethers, chenodeoxycholate, deoxycholate, alkali metal salicylate, pharmaceutically acceptable edetate, and pharmaceutically acceptable salts and analogues thereof, and c. an effective amount of a pharmaceutically acceptable carrier, wherein the composition is free of any active pharmaceutical agents.